Abstract
The potential role of transforming growth factor-β in in vivo resistance was examined by administration of transforming growth factor-β-neutralizing antibodies to animals bearing the EMT-6/Parent tumor or the antitumor alkylating resistant tumors, EMT-6/CTX or EMT-6/CDDP. Treatment of tumor-bearing animals with anti-TGF-β antibodies by intraperitoneal injection daily on days 0–8 post-tumor cell implantation increased the sensitivity of the EMT-6/Parent tumor to cyclophosphamide (CTX) and cisplatin (CDDP) and markedly increased the sensitivity of the EMT-6/CTX tumor to CTX and the EMT-6/CDDP tumor to CDDP, as determined by tumor cell survival assay. Bone marrow granulocyte-macrophage colony-forming units (CFU-GM) survival was determined from these same animals. The increase in the sensitivity in the tumors upon treatment with the anti-TGF-β antibodies was also observed in increased sensitivity of the bone marrow CFU-GM to CTX and CDDP. Treatment of non-tumor-bearing animals with the anti-TGF-β regimen did not alter blood ATP or serum glucose level but did decrease serum lactate levels. This treatment also decreased hepatic glutathione, glutathione S-transferase, glutathione reductase, and glutathione peroxidase in non-tumor-bearing animals by 40–60% but increased hepatic cytochrome P450 reductase in these normal animals. Animals bearing the EMT-6/CTX and EMT-6/CDDP tumors had higher serum lactate levels than normal or EMT-6/Parent tumor-bearing animals; these were decreased by the anti-TGF-β regimen. Treatment of animals bearing any of the three tumors with the anti-TGF-β regimen decreased by 30–50% the activity of hepatic glutathione S-transferase and glutathione peroxidase, and increased by 35–80% the activity of hepatic cytochrome P450 reductase. In conclusion, treatment with transforming growth factor-β-neutralizing antibodies restored drug sensitivity in the alkylating agent-resistant tumors, altering both the tumor and host metabolic states.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Author information
Authors and Affiliations
Additional information
Received: 27 January 1995/Accepted: 9 June 1995
Rights and permissions
About this article
Cite this article
Teicher, B., Holden, S., Ara, G. et al. Transforming growth factor-β in in vivo resistance. Cancer Chemother Pharmacol 37, 601–609 (1996). https://doi.org/10.1007/s002800050435
Issue Date:
DOI: https://doi.org/10.1007/s002800050435